Boundless Bio, Inc. (BOLD)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.50
- As of
Kresmion compiles this page from BOLD's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Boundless Bio, Inc. (BOLD): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-28.
See the full BOLD dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for BOLD on one page. Preview it with sample data, then open it live with a free account.
Preview the BOLD dossierActive events for BOLD
- mediumEarnings below estimates
Q2-2026: Missed consensus by 79.2%, EPS $-1.06 vs $-0.5916 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 72% of BOLD (2026Q2)
- high13F: large increase
MILLENNIUM MANAGEMENT LLC added +379% to BOLD (2026Q2)
- mediumEarnings below estimates
Q2-2025: Missed consensus by 5.6% - EPS $-0.7 vs $-0.663 estimate
- mediumEarnings below estimates
Missed consensus by 5.6% - EPS $-0.7 vs $-0.663 estimate
FREE, NO ACCOUNT
Every event on BOLD, as it fires
You are seeing 5 of 6 events recorded on BOLD since 2026-05-16.
The five above landed across 4 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in BOLD (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 10170A100 · 2026Q2 | $1.2M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 10170A100 · 2026Q2 | $1.2M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 10170A100 · 2026Q2 | $363K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BOLD
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
BOLD against its peers
BOLD's return on equity of -59.0% ranks in the 69th percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-04-30 and 2025-12-31.
| Metric | BOLD | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 11.2M | n/a | 15 |
| Gross margin | n/a | 66.9% | n/a | 5 |
| Operating margin | n/a | -208.8% | n/a | 12 |
| Net margin | n/a | -123.3% | n/a | 13 |
| Return on equity | -59.0% | -121.2% | 69 | 17 |
Peers (24): OSTX, HRTX, CRBU, XLO, INKT, GOSS, VRCA, ELOX, ELTX, HOWL, XBIT, RNXT, RNTX, GANX, ONCY, FBIO, SGMOQ, LONA, AURX, HYFT, CNTB, TENX, SPRO, IMA. Left out: APLM (period gap). Fiscal periods ending between 2025-04-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (BOLD: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow BOLD on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to BOLD for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.